Trial Profile
Repeated anti-CEA-radioimmunotherapy (RAIT) with 131iodine-labetuzumab after resection of colorectal liver metastases (CLM): a prospective phase II study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2015
Price :
$35
*
At a glance
- Drugs Labetuzumab I 131 (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Sponsors Immunomedics
- 25 Jun 2007 New trial record.